Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma

NCT07416890 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Pirtobrutinib
Sintilimab
Central Nervous System Lymphoma

Interventions

DRUG: Thiotepa, Pirtobrutinib , Sintilimab(TPS)

Sponsor

Zhejiang Cancer Hospital